Oscar Health’s Hold Rating: Balancing Positive EBITDA with Market Uncertainties and Risk Challenges

Analyst Stephen Baxter of Wells Fargo reiterated a Hold rating on Oscar Health (OSCR – Research Report), retaining the price target of $16.00.

Stephen Baxter has given his Hold rating due to a combination of factors surrounding Oscar Health’s recent performance and market conditions. While Oscar Health reported a better-than-expected EBITDA for the first quarter and maintained its guidance, the positive reaction in the market appears to be more about positioning rather than a clear indication of sustained growth throughout the year. The company faces challenges with higher medical loss ratios (MLR) and increased utilization, which are partially offset by lower selling, general, and administrative expenses (SG&A).
Risk adjustment is a focal point, as Oscar Health anticipates higher risk scores due to increased utilization. However, since risk adjustment in the exchanges is a zero-sum game, any improvement in Oscar’s risk scores may not necessarily enhance its competitive position if peers experience similar increases. Additionally, uncertainties in the exchange market and the impact of payment integrity enforcement on enrollment cycles add to the cautious outlook. Despite some positive developments, such as minimal churn from members affected by failure to reconcile (FTR), these factors contribute to a Hold rating as the market remains unsettled.

OSCR’s price has also changed moderately for the past six months – from $13.640 to $17.020, which is a 24.78% increase.